ClinicalTrials.gg
CompletedNCT00660504Updated Jul 18, 2014Results posted

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

A Phase 3 interventional study of Amrubicin Hydrochloride and Etoposide-Cisplatin combined chemotherapy in Lung Cancer, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Completed at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. (formerly part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 844 studies in Lung Neoplasms with a site in China — 371 open to participants now, 418 under way, 34 of them phase 3. Lung Neoplasms · China.

Enrollment
108th of 585
300 · median 90
Started
2008
with 5 others
Phase 3
66 of 844
17 open now
Registered
14th of 844
by date

Among the 844 studies in Lung Neoplasms with a site in China, this one is the 108th largest by enrollment of the 585 interventional ones that give a count, is one of 6 that started in 2008, is one of 66 in phase 3, and was the 14th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

371 of the 844 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

366 more — sign in →

All 371 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 844 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study drug(Amrubicin)is believed to work by stopping the tumor cell in your body from growing. The purpose of this study is to evaluate the efficacy and safety of amrubicin with cisplatin compared to etoposide-cisplatin in the first-line treatment in extensive disease small cell lung cancer The subject, who is randomized to AP group may be involved into a pharmacokinetic study of amrubicin and the metabolites: amrubicinol voluntarily.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Extensive Disease-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically/ proven small cell lung cancer
  • Extensive disease
  • No prior chemotherapy regimen
  • Age 18 years or older
  • performance status of 0-1

Exclusion criteria

Exclusion Criteria:

  • requiring treatment
  • Treatment (Surgical or radiotherapy)of primary tumor
  • Interstitial pneumonia or pulmonary fibrosis
  • Abnormal cardiac function or myocardial infraction within 6 months before study enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    1

    Amrubicin Hydrochloride-Cisplatin combined chemotherapy

    Drug: Amrubicin Hydrochloride

  • Active comparator
    2

    Etoposide-Cisplatin combined chemotherapy

    Drug: Etoposide-Cisplatin combined chemotherapy

Interventions

  • Amrubicin Hydrochloride combined with cisplatin

  • DrugEtoposide-Cisplatin combined chemotherapy

    combined chemotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: 1.5 years after last subject enrolled

Secondary outcomes

  1. Progression-Free Survival

    Time frame: 1.5 years after last subject enrolled

  2. Objective Response Rate

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: participants were followed for the duration of the study, an average of 12 weeks

Other outcomes

  1. Overall Survival at 6 and 12 Months

    Time frame: 6 and 12 months.

07

Results

Posted Jul 4, 2014

Participant flow

Participant flow — Overall Study
MilestoneAmrubicin Combined With Cisplatin GroupEtoposide Combined With Cisplatin Group
Started149151
Completed149150
Not completed01

Outcome measures

PrimaryOverall Survival
Time frame:
1.5 years after last subject enrolled
Reported as:
Median · month
Overall Survival
monthAmrubicin Combined With Cisplatin GroupEtoposide Combined With Cisplatin Group
Overall Survival11.79 (11.01 to 12.62)10.28 (9.23 to 11.96)
Other pre-specifiedOverall Survival at 6 and 12 Months
Time frame:
6 and 12 months.
Reported as:
Number · percentage of patients
Overall Survival at 6 and 12 Months
percentage of patientsAmrubicin Combined With Cisplatin GroupEtoposide Combined With Cisplatin Group
6-month89.26 (83.07 to 93.28)86.00 (79.34 to 90.64)
12-month48.59 (40.31 to 56.36)41.93 (33.97 to 49.68)
SecondaryProgression-Free Survival
Time frame:
1.5 years after last subject enrolled
Reported as:
Median · month
Progression-Free Survival
monthAmrubicin Combined With Cisplatin GroupEtoposide Combined With Cisplatin Group
Progression-Free Survival6.83 (6.11 to 7.39)5.72 (5.06 to 6.93)
SecondaryObjective Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
participants were followed for the duration of the study, an average of 12 weeks
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsAmrubicin Combined With Cisplatin GroupEtoposide Combined With Cisplatin Group
Objective Response Rate69.8057.33

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amrubicin, Anticancer, Injection—21/149 (14.1%)149/149 (100%)
Etoposide, Anticancer, Injection—8/150 (5.3%)148/150 (98.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventAmrubicin, Anticancer, InjectionEtoposide, Anticancer, Injection
Neutrophil count decreasedInvestigations7/1490/150
White blood cell count decreasedInvestigations6/1490/150
Bone marrow failureBlood and lymphatic system disorders5/1493/150
Febrile neutropenia syndromeBlood and lymphatic system disorders3/1490/150
Platelet count decreasedInvestigations3/1491/150
DiarrheaGastrointestinal disorders2/1490/150
feverInfections and infestations2/1490/150
HypokalemiaMetabolism and nutrition disorders2/1490/150
Cerebral infarctionNervous system disorders1/1492/150
AgranulocytosisBlood and lymphatic system disorders1/1490/150
Most frequent other events
Showing 10 of 31
Most frequent other events
EventAmrubicin, Anticancer, InjectionEtoposide, Anticancer, Injection
Neutrophil count decreasedBlood and lymphatic system disorders99/14985/150
White blood cell count decreasedBlood and lymphatic system disorders97/14985/150
NauseaGastrointestinal disorders72/14970/150
vomitGastrointestinal disorders63/14963/150
Decreased appetiteGastrointestinal disorders60/14950/150
Platelet count decreasedBlood and lymphatic system disorders54/14940/150
Lower hemoglobinBlood and lymphatic system disorders49/14950/150
AnemiaBlood and lymphatic system disorders48/14948/150
Bone marrow failureBlood and lymphatic system disorders46/14946/150
ConstipationGastrointestinal disorders32/14925/150

Baseline characteristics

Age, Continuous
Age, Continuous(years)Amrubicin, Anticancer, InjectionEtoposide, Anticancer, InjectionTotal
Mean56.1 ± 10.0357.45 ± 9.7856.78 ± 9.92
Sex: Female, Male
Sex: Female, Male(Participants)Amrubicin, Anticancer, InjectionEtoposide, Anticancer, InjectionTotal
Female353772
Male114113227
Region of Enrollment
Region of Enrollment(participants)Amrubicin, Anticancer, InjectionEtoposide, Anticancer, InjectionTotal
China149150299
08

Study locations

15 sites
  • Fuzhou, Fujian, China
  • Lanzhou, Gansu, China
  • Guangzhou, Guangdong, China
  • Changsha, Hunan, China
  • Nanjing, Jiangsu, China
  • Nanchang, Jiangxi, China
  • Changchun, Jilin, China
  • Dalian/Shenyang, Liaoning, China
  • Shenyang, Liaoning, China
  • Xian, Shanxi, China
  • Chengdu, Sichuan, China
  • Hangzhou, Zhejiang, China
  • Beijing, China
  • Shanghai, China
  • Tianjin, China
09

References and documents

Publications

  • Sun Y, Cheng Y, Hao X, Wang J, Hu C, Han B, Liu X, Zhang L, Wan H, Xia Z, Liu Y, Li W, Hou M, Zhang H, Xiu Q, Zhu Y, Feng J, Qin S, Luo X. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer. 2016 Apr 9;16:265. doi: 10.1186/s12885-016-2301-6. PubMed 27061082 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Feb 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2008
First posted
Apr 17, 2008
Start
Apr 2008
Primary completionActual
Feb 2012
CompletionActual
Aug 2012
Results first posted
Jul 4, 2014
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00660504
Responsible party
Sponsor
First posted
Apr 17, 2008
Start date
Apr 2008
Primary completion
Feb 2012
Completion
Aug 2012
Results posted
Jul 4, 2014
Last update
Jul 18, 2014

Study contacts

Yan Sun, MD
principal investigator · Cancer hospital, Chinese Academy of Medical Science

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amrubicin

Start the discussion